These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Subscribe To Our Newsletter & Stay Updated
